On the stock market since 2001, it operates in the world of health and science. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Revenue is spread across several lines; no single product carries the company.
Average growth of 5% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
It pays out $0.48 per share each year — regular cash for whoever holds the stock.
A loss of $247.2M against $6.0B in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, KND sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: KND has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.